| Nov 12 |
Dyne Therapeutics GAAP EPS of -$0.96 misses by $0.25
|
| Nov 12 |
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 11 |
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
|
| Oct 24 |
Dyne cut to neutral by J.P. Morgan on stock's outperformance
|
| Oct 22 |
Looking Into Dyne Therapeutics's Recent Short Interest
|
| Oct 21 |
Top small-cap stock picks from Morgan Stanley following the group's upgrade to neutral
|
| Oct 9 |
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
|
| Oct 7 |
Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now
|
| Sep 23 |
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
|
| Sep 6 |
CEO, President & Director of Dyne Therapeutics John Cox Buys 640% More Shares
|
